Cannabidiol Reduces Seizures in Children with Severe Epilepsy
Randomized placebo-controlled clinical trial shows decline in seizures with cannabidiol in children with drug-resistant Dravet syndrome
Results from a double-blind, placebo-controlled trial revealed that children with Dravet syndrome, a severe form of epilepsy, had fewer seizures after taking a daily oral solution of the cannabis compound called cannabidiol, which does not have the psychoactive properties of marijuana. Over a 14-week treatment with cannabidiol, convulsive seizures dropped from a monthly average of 12.4 to 5.9. In comparison, seizures in the placebo group decreased from a monthly average of 14.9 to 14.1. During the study, seizures stopped completely in 5 percent of patients taking cannabidiol. “Seizures in Dravet syndrome are extremely difficult to control and they can be deadly,” says study co-author Linda Laux, MD, from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago. “Our results are encouraging, especially considering that we don’t have any antiepileptic drugs approved for Dravet syndrome in the U.S.”
Click here to read more.
Kranzler Chicago Review Course in Neurosurgery
Jan. 24-31, 2020; Chicago
46th Annual Richard Lende Winter Neurosurgery Conference
Jan. 31-Feb. 3, 2020; Snowbird, Utah
Third Annual Cedars Sinai Intracranial Hypotension Symposium
Feb. 8, 2020; Los Angeles
2020 Managing Coding and Reimbursement Challenges
Feb. 14-16, 2020; Las Vegas
13th Annual International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery
Feb. 21-23, 2020; Lake Buena Vista, Fla.